Navigation Links
Syndax Pharmaceuticals to Present at BIO Investor Forum
Date:9/28/2010

WALTHAM, Mass., Sept. 28 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the 9th Annual BIO Investor Forum Tuesday, October 5, 2010 at the Palace Hotel in San Francisco.

Dr. Horobin's presentation will be given at 11:30 am PT (2:30 pm ET) and will include an overview of the upcoming milestones including the ongoing phase 2 clinical program for entinostat in breast, lung, colorectal cancer and hematologic malignancies.

The presentation will be available at Syndax's website, www.syndax.com.

About SyndaxSyndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.

Syndax holds rights to entinostat from Bayer Schering Pharma and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.  For more information please visit www.syndax.com.Contact InformationJoanna Horobin, M.D.

Danielle Bertrand Syndax Pharmaceuticals, Inc

WCG Tel: 781-419-1402

Tel: 415-946-1056 jhorobin@syndax.com

dbertrand@wcgworld.com
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Sterlitech is proud to debut its multi-line, fully ... AMTA Membrane Technology Conference in Orlando. This new ... engineering and customer feedback, which has resulted in a ... across an array of disciplines. It is designed ... of researchers and engineers alike and is ideal for ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO Controversy , ... The GMO TRUTH podcast on both ITunes and at The ... mission to discover the truth and change the world. ... truth about the GMOs in our food supply,” adds a ... an expansion of the documentary/investigative film-making methodology in place at ...
(Date:2/27/2015)... 27, 2015 A paper published today, ... portfolio " in Science Translational Medicine, ... to reduce the risk associated with investing in ... new levels of funding for developing so-called "orphan" ... unique collaboration between scientists at the National Center ...
(Date:2/27/2015)... Feb. 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) ... trial of BNC105 in patients with metastatic renal cancer ... Orlando, Florida . The data will be presented ... of Hope Comprehensive Cancer Center in California ... The new data identifies Ferritin and IL-8 as two ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2The Walk a Mile Project Launches “GMO Truth” Podcast 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5
... and WEYBRIDGE, England, Dec. 6, 2010 ViroPharma ... the global leader in developing long-term strategic solutions ... companies have partnered to facilitate access to certain ...  ViroPharma,s NPP, developed and managed by Idis, will ...
... Clarient, Inc. ("Clarient") (Nasdaq: CLRT ) announced today ... Crane Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of ... to acquire all of the outstanding shares of capital stock ... Offer from midnight, New York City time, at the end ...
... Institute (BRI), the research arm of Baylor Health Care ... with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly ... at the Baylor Institute for Immunology Research (BIIR), a ... BIIR,s leading position in human immunology with particular focus ...
Cached Biology Technology:ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program 2ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program 3Clarient Tender Offer Extended; Clarient Makes Additional Disclosures to Settle Litigation 2Clarient Tender Offer Extended; Clarient Makes Additional Disclosures to Settle Litigation 3Clarient Tender Offer Extended; Clarient Makes Additional Disclosures to Settle Litigation 4Roche, Baylor Research Institute Partner in Human Immunology Research 2
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , January 28, 2015 ... Analysis, Size And Segment Forecasts To 2020 has Been ... IR camera market is expected to reach USD 5.10 ... Grand View Research, Inc. IR cameras help identify the ... are expected to witness surging demand in medical imaging ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... January 28, 2014 Scientists at Harvard University ... of the natural nanoscale photonic device that enables a ... inspire improved protective camouflage for soldiers on the battlefield. ... sea," can rapidly alter both the color and pattern ...
... A University of Colorado Cancer Center study published today ... and Physics shows that patients taking crizotinib for ... use up to three courses of targeted radiation therapy ... of resistant disease allows patients to continue treating the ...
... advanceselectronic devices, the iPhone, medical implants, disease detection ... of revolutionary interfaces. The study of creating and ... engineeringis one of the most exciting research frontiers. ... of Engineering will welcome leading engineers, physicists, chemists, ...
Cached Biology News:'Chameleon of the sea' reveals its secrets 2'Chameleon of the sea' reveals its secrets 3'Weeding the garden' lets ALK+ lung cancer patients continue crizotinib 2'Weeding the garden' lets ALK+ lung cancer patients continue crizotinib 3Interfacing with the future 2
... Activins are polypeptide hormones which ... (TGF-) superfamily. The TGF- superfamily is ... factors which control many aspects of ... (1). Other members incude TGF-s, bone ...
... hormones which belong to the transforming ... superfamily is a large group of ... aspects of development, reproductive function and ... TGF-s, bone morphogenetic proteins, growth differentiation ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... Detection of the yolk protein Vtg in ... simple and sensitive biomarker for endocrine disrupting chemicals ... Vtg has become an accepted screening test for ... Vtg (rainbow trout) EIA kit is a double-antibody ...
Biology Products: